Amber Tong – Page 21 – Endpoints News

about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW

Amber Tong on LinkedIn

author articles

Q&A: Can inhaled vaccines mount comeback for one-time leader in China's Covid race?

3 years ago

ICYMI: 'What could they possibly buy?' Sanofi's Paul Hudson talks M&A hesitation at #JPM23

3 years ago

Unpacking FDA’s latest Alzheimer’s OK; A look at all drugs approved in 2022; Moderna’s deal spree; Pfizer ...

3 years ago

Six years later, SEC drops claims of accounting fraud against biotech exec

3 years ago

Updated: Sickle cell gene editing startup halts trial after flagging serious side effect in first patient

3 years ago

Pfizer tags early research programs for 'externalization' as it narrows focus in rare disease, cancer

3 years ago

While keeping eye on snap NASH OK, Inventiva tests out alternative PhIII path

3 years ago

Deciphera revives hopes for Qinlock with subgroup analysis, plots new PhIII — but market reaction is muted

3 years ago

Tiny IPO closes out Nasdaq's barren biotech year

3 years ago

Riding on positive PhIII NASH data, Madrigal raises $300M for road to FDA

3 years ago

Catching up in multiple myeloma, Pfizer taps ORIC for BCMA combo study

3 years ago

Celyad scraps one final clinical CAR-T program as clock ticks

3 years ago

After PhII results disappoint, Merck excises eye drugs from longtime pact with NGM

3 years ago

Blaming placebo response for 'uninterpretable' PhIII results, ContraFect calls for new antibiotic study

3 years ago

Entrada hit with clinical hold on Duchenne drug

3 years ago

Emerging from hepatitis B flops, Assembly Bio showcases early data on next-gen drugs

3 years ago

Sanofi plucks three more NK cell engagers from French biotech partner, putting down €25M cash

3 years ago

WIB22: Hear from our 2022 Women in Biopharma R&D honorees, and catch our panel on empowering women

3 years ago

Endpoints honors 20 women leaders; Vertex teams up with neighbor; Pfizer rival impresses; and more

3 years ago

WIB22: Chasing after ever-evolving science takes a drug hunter across the pond

3 years ago

Autolus tips its hand, bags $220M as CAR-T showdown with Gilead looms

3 years ago

WIB22: She reshaped migraine science and led key trials for new drugs, but Sheena Aurora isn’t done

3 years ago

Sanofi walks away from $500M deal, leaving Revolution alone in pushing SHP2/KRAS combo

3 years ago

Neurocrine's $50M bet on Idorsia drug flames out in second PhII

3 years ago

First page Previous page 18 19 202122 23 24 Next page Last page